Similarly, the reduction of tumor immune infiltrates with PRC2 loss was seen across all major subclasses of immune cells, including MHC-II+CD11c+ DCs, TCRβ+ T cells (both CD4+ and CD8+), F4/80hiCD11b+ macrophages, and to a lesser extent B220+ B cells (Figure 6F and Supplemental Figure 6H). Here, ITGAX is linked to neoplasm.